乌斯特基努马
银屑病
英夫利昔单抗
医学
阿达木单抗
单核苷酸多态性
塞库金单抗
白细胞介素17
内科学
伊克泽珠单抗
单变量分析
肿瘤坏死因子α
免疫学
基因型
细胞因子
多元分析
基因
生物
银屑病性关节炎
生物化学
作者
Rocío Prieto‐Pérez,G. Solano‐López,Teresa Cabaleiro,Manuel Román,Dolores Ochoa,María Talegón,Ofelia Baniandrés,J.L. López‐Estebaranz,P. de la Cueva,E. Daudén,Francisco Abad‐Santos
出处
期刊:Pharmacogenomics
[Future Medicine]
日期:2015-10-01
卷期号:16 (15): 1723-1731
被引量:50
摘要
Psoriasis improves when IL-17 is blocked. Anti-TNF drugs reduce the IL-17 signaling pathway, and anti-IL-17 drugs are being developed to treat moderate-to-severe psoriasis. We analyzed three SNPs in IL-17A (rs2275913 and rs10484879) and IL-17F (rs763780) to look for an association with psoriasis and/or with response to anti-TNF drugs or ustekinumab. We included 197 healthy controls and 194 patients with moderate-to-severe psoriasis. The results of the univariate analysis showed an association between rs10484879 and psoriasis, although this relationship disappeared after adjustment for HLA-C (rs12191877). We also found an association between rs763780 (IL-17F) and response to ustekinumab (n = 70) and infliximab (n = 37) at 3 and 6 months and an association between rs763780 and the response to adalimumab at 6 months (n = 67).
科研通智能强力驱动
Strongly Powered by AbleSci AI